FEMY — what changed in the latest 10-Q
A section-by-section comparison of FEMY's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-08 vs the prior 10-Q · 2025-11-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +75 | −56 | ~17 | 45 |
| Market risk (Item 3) | Text added/removed | +74 | −55 | ~17 | 45 |
| Controls & procedures | Text added/removed | +74 | −55 | ~17 | 45 |
| Legal proceedings | Text added/removed | +74 | −55 | ~17 | 45 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +73 | −55 | ~17 | 45 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-08
Item 3Quantitative and Qualitative Disclosures About Market Risk38
Item 2Unregistered Sales of Equity Securities and Use of Proceeds42
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Conversion of November 2025 convertible notes into common stock
Payment of November 2023 convertible note interest in common stock
Text removed vs the prior filing · source: 10-Q · 2025-11-14
Management’s Discussion and Analysis of Financial Condition and Results of Operations
• our ability to successfully grow sales of FemBloc permanent birth control in the European Union;
Net loss attributable to common stockholders, basic and diluted
Net loss per share attributable to common stockholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-05-08
Item 2Unregistered Sales of Equity Securities and Use of Proceeds42
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Conversion of November 2025 convertible notes into common stock
Payment of November 2023 convertible note interest in common stock
Deferred offering costs reclassified to additional paid-in capital
Text removed vs the prior filing · source: 10-Q · 2025-11-14
• our ability to successfully grow sales of FemBloc permanent birth control in the European Union;
Net loss attributable to common stockholders, basic and diluted
Net loss per share attributable to common stockholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
Issuance of common stock in connection with June 2025 financing, net of issuance costs
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-08
Item 2Unregistered Sales of Equity Securities and Use of Proceeds42
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Conversion of November 2025 convertible notes into common stock
Payment of November 2023 convertible note interest in common stock
Deferred offering costs reclassified to additional paid-in capital
Text removed vs the prior filing · source: 10-Q · 2025-11-14
• our ability to successfully grow sales of FemBloc permanent birth control in the European Union;
Net loss attributable to common stockholders, basic and diluted
Net loss per share attributable to common stockholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
Issuance of common stock in connection with June 2025 financing, net of issuance costs
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-08
Item 2Unregistered Sales of Equity Securities and Use of Proceeds42
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Conversion of November 2025 convertible notes into common stock
Payment of November 2023 convertible note interest in common stock
Deferred offering costs reclassified to additional paid-in capital
Text removed vs the prior filing · source: 10-Q · 2025-11-14
• our ability to successfully grow sales of FemBloc permanent birth control in the European Union;
Net loss attributable to common stockholders, basic and diluted
Net loss per share attributable to common stockholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
Issuance of common stock in connection with June 2025 financing, net of issuance costs
Other information
Text added vs the prior filing · source: 10-Q · 2026-05-08
Issuance of common shares in payment of 2023 convertible note interest, including related parties
Conversion of November 2025 convertible notes into common stock
Payment of November 2023 convertible note interest in common stock
Deferred offering costs reclassified to additional paid-in capital
Femasys Inc. (the “Company” or “Femasys”) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical innovator, addressing significant unmet needs in women's health worldwide, with a broad patent-protected portfolio of disruptive, …
Text removed vs the prior filing · source: 10-Q · 2025-11-14
• our ability to successfully grow sales of FemBloc permanent birth control in the European Union;
Net loss attributable to common stockholders, basic and diluted
Net loss per share attributable to common stockholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
Issuance of common stock in connection with June 2025 financing, net of issuance costs
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice